|
1
|
Zhang XR, Chien PN, Nam SY and Heo CY: Anaplastic large cell lymphoma: Molecular pathogenesis and treatment. Cancers (Basel). 14:16502022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leventaki V, Bhattacharyya S and Lim MS: Pathology and genetics of anaplastic large cell lymphoma. Semin Diagn Pathol. 37:57–71. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kaseb H, Mukkamalla SKR and Rajasurya V: Anaplastic large cell lymphoma. StatPearls Treasure Island (FL): 2022
|
|
4
|
Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, et al: ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-cell lymphoma project. Blood. 111:5496–5504. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sibon D, Nguyen DP, Schmitz N, Suzuki R, Feldman AL, Gressin R, Lamant L, Weisenburger DD, Rosenwald A, Nakamura S, et al: ALK-positive anaplastic large-cell lymphoma in adults: An individual patient data pooled analysis of 263 patients. Haematologica. 104:e562–e565. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Morel A, Brière J, Lamant L, Loschi M, Haioun C, Delarue R, Tournilhac O, Bachy E, Sonet A, Amorim S, et al: Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study. Eur J Cancer. 83:146–153. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang QQ, Jiang Y and Naranmandura H: Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases. Metallomics. 12:326–336. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wahiduzzaman M, Ota A and Hosokawa Y: Novel mechanistic insights into the anti-cancer mode of arsenic trioxide. Curr Cancer Drug Targets. 20:115–129. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Z, Chen Q, Zhang W, Si G, Li J, Jiao D and Han X: Efficacy and safety of the arsenic trioxide/lipiodol emulsion in the transcatheter arterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma. Can J Gastroenterol Hepatol. 2021:55657932021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Pan D, Yang H, Huang J, He Z, Li H and Li D: Effects of arsenic trioxide combined with platinum drugs in treatment of cervical cancer: A protocol for systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 99:e229502020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kutny MA, Alonzo TA, Abla O, Rajpurkar M, Gerbing RB, Wang YC, Hirsch BA, Raimondi S, Kahwash S, Hardy KK, et al: Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: A report from the children's oncology group AAML1331 trial. JAMA Oncol. 8:79–87. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhong L, Xu F and Chen F: Arsenic trioxide induces the apoptosis and decreases NF-κB expression in lymphoma cell lines. Oncol Lett. 16:6267–6274. 2018.PubMed/NCBI
|
|
13
|
Li XY, Li Y, Zhang L, Liu X, Feng L and Wang X: The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt/β-catenin pathway and DNA methyltransferase-1. Oncol Rep. 38:3114–3120. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li HM, Long Y, Qing C, Yu M, Li ZH, Zhang XM, Li XJ, Chen YJ, Zhang YL and Liang Y: Arsenic trioxide induces apoptosis of Burkitt lymphoma cell lines through multiple apoptotic pathways and triggers antiangiogenesis. Oncol Res. 19:149–163. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li CL, Wei HL, Chen J, Wang B, Xie B, Fan LL and Li LJ: Arsenic trioxide induces autophagy and antitumor effects in Burkitt's lymphoma Raji cells. Oncol Rep. 32:1557–1563. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kouhpaikar H, Sadeghian MH, Rafatpanah H, Kazemi M, Iranshahi M, Delbari Z, Khodadadi F, Ayatollahi H and Rassouli FB: Synergy between parthenolide and arsenic trioxide in adult T-cell leukemia/lymphoma cells in vitro. Iran J Basic Med Sci. 23:616–622. 2020.PubMed/NCBI
|
|
17
|
Yue LM, Chau D, Kwong YL and Tse E: Arsenic trioxide inhibits anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma through targeting ALK-fusion oncoprotein. Br J Haematol. 194:1085–1090. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Piao W, Chau D, Yue LM, Kwong YL and Tse E: Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma. Leukemia. 31:522–526. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Park SH, Kim S, Ko OB, Koo JE, Lee D, Jeong YP, Huh J, Kim SB, Kim SW, Lee JL and Suh C: ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: A single center experience. Korean J Intern Med. 21:159–164. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M, Hatoum H, Rahimi H, Maleki M, Rafatpanah H, et al: Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood. 113:6528–6532. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, et al: Revised response criteria for malignant lymphoma. J Clin Oncol. 25:579–586. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu HH, Hu J, Lo-Coco F and Jin J: The simpler, the better: Oral arsenic for acute promyelocytic leukemia. Blood. 134:597–605. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao H, Sun G, Kong D, Zhang Y, Shi W, Zhao M, Hong L and Qiao Z: A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma. Med Oncol. 32:792015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hermine O, Dombret H, Poupon J, Arnulf B, Lefrère F, Rousselot P, Damaj G, Delarue R, Fermand JP, Brouet JC, et al: Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J. 5:130–134. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Marçais A, Cook L, Witkover A, Asnafi V, Avettand-Fenoel V, Delarue R, Cheminant M, Sibon D, Frenzel L, de Thé H, et al: Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia/lymphoma. Retrovirology. 17:52020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang J, Yao C, Liu Y, Yuan J, Wu L, Hosoi K, Yu S, Huang C, Wei H and Chen G: Arsenic trioxide induces expression of BCL-2 expression via NF-κB and p38 MAPK signaling pathways in BEAS-2B cells during apoptosis. Ecotoxicol Environ Saf. 222:1125312021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Daugrois C, Bessiere C, Dejean S, Anton-Leberre V, Commes T, Pyronnet S, Brousset P, Espinos E, Brugiere L, Meggetto F and Lamant L: Gene expression signature associated with clinical outcome in ALK-positive anaplastic large cell lymphoma. Cancers (Basel). 13:55232021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen MT, Fu XH, Huang H, Wang Z, Fang XJ, Yao YY, Ren QG, Chen ZG and Lin TY: Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Leuk Lymphoma. 62:571–580. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Peng X, Xiong X, Li Y, Feng C, Liu H, Wu P, Li C and Weng W: Encouraging early outcomes of treatment with arsenic trioxide combined with chemotherapy for alveolar rhabdomyosarcoma in children: 4 Case reports. Front Oncol. 11:7516232021. View Article : Google Scholar : PubMed/NCBI
|
